INPP1 and breast carcinoma: Differentially expressed proteins were analyzed to construct a diagnostic model, which was validated in an independent cohort (111 breast cancer patients [56 early-stage, 55 late-stage] vs. 95 healthy controls).<h4>Results</h4>The combination of INPP1 (first reported as downregulated in breast cancer serum) and ARHGAP25 demonstrated high diagnostic accuracy, achieving AUCs of 0.8458 (discovery cohort) and 0.8506 (validation cohort).